Foghorn Therapeutics (FHTX) Net Cash Flow (2019 - 2026)

Foghorn Therapeutics' Net Cash Flow history runs 8 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 21.81% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $28.2 million (up 254.6% YoY), while the FY2025 annual figure was $27.0 million, up 208.37% from the prior year.
• Net Cash Flow was $6.8 million for Q1 2026 at Foghorn Therapeutics, up from -$8.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $112.5 million in Q1 2022 to a low of -$152.4 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$703294.1 across 5 years, with a median of $6.8 million in 2026.
• Biggest YoY gain for Net Cash Flow was 745.28% in 2024; the steepest drop was 744.84% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$35.4 million in 2022, then soared by 128.32% to $10.0 million in 2023, then plunged by 122.17% to -$2.2 million in 2024, then plunged by 280.31% to -$8.5 million in 2025, then surged by 180.24% to $6.8 million in 2026.
• The last three Net Cash Flow figures came in at $6.8 million (Q1 2026), -$8.5 million (Q4 2025), and $16.8 million (Q3 2025), per Business Quant data.